Postprostatectomy prostate cancer treated with radiation therapy: adverse features and androgen deprivation therapy use in a statewide consortium
Within the Michigan Radiation Oncology Quality Consortium, more than half who received postprostatectomy RT had high-risk features; nearly 30% required consolidation for persistently positive PSA. Androgen deprivation therapy was associated with high-risk features, but few received androgen deprivation therapy prolongation or intensification. Studies are needed to personalize androgen deprivation therapy, especially for those with persistent PSA, who are frequently treated yet underrepresented in trials.
Authors
- Mark M. Zaki (ORCID: https://orcid.org/0000-0002-5155-042X)
- Huiying Yin
- S. Miller (ORCID: https://orcid.org/0000-0002-7159-6871)
- Todd Matthew Morgan (ORCID: https://orcid.org/0000-0002-1140-0603)
- D.K. Heimburger (ORCID: https://orcid.org/0000-0002-7080-3488)
- Robert Timothy Dess (ORCID: https://orcid.org/0000-0003-2331-3758)
- Patrick A. McLaughlin (ORCID: https://orcid.org/0000-0002-1633-5409)
- Mazen Mislmani
- Danielle Kendrick
- Matthew J. Schipper (ORCID: https://orcid.org/0000-0001-6728-4720)
- Will Jackson (ORCID: https://orcid.org/0000-0001-8709-5978)
- Michael Dykstra (ORCID: https://orcid.org/0000-0003-0834-7669)
- Kevin Ginsberg
- M. Mietzel (ORCID: https://orcid.org/0000-0003-3222-9849)
- S.N. Regan
- Tudor Borza (ORCID: https://orcid.org/0000-0001-9164-6605)
Institutions
- Munson Medical Center (US)
- Wayne State University (US)
- University of Michigan (US)
- Henry Ford Hospital (US)
- The Barbara Ann Karmanos Cancer Institute (US)
- Michigan Medicine (US)
- Providence Park Hospital (US)
- Covenant HealthCare (US)
- West Michigan Cancer Center (US)
Publication Details
- Journal
- JNCI Cancer Spectrum
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1093/jncics/pkaf112
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00